公开(公告)号：ES2818948T3

公开(公告)日：2021-04-14

申请号：ES14886988

申请日：2014-10-28

Applicant: DEV CT BIOTECHNOLOGY ,  CHANG GUNG MEMORIAL HOSPITAL ,  ACADEMIA SINICA

Inventor： YU ALICE ,  YU JOHN ,  WANG YA-HUI ,  HSU CHUAN-LUNG ,  CHEN YI-CHANG ,  LOK YING-YUNG

IPC: G01N33/574 ,  C07K16/30

Abstract: Un anticuerpo contra la proteína con dominios de superhélice transmembrana 3 (TMCC3), o un fragmento de unión de la misma, en donde el anticuerpo comprende las siguientes secuencias de CDR: la secuencia de CDRH1 es el SEQ ID NO: 102, la secuencia de CDRH2 es el SEQ ID NO: 226, la secuencia de CDRH3 es el SEQ ID NO: 350, la secuencia de CDRL1 es el SEQ ID NO: 474, la secuencia de CDRL2 es el SEQ ID NO: 598, y la secuencia de CDRL3 es el SEQ ID NO: 722, o la CDRH1 es el SEQ ID NO: 101, la CDRH2 es el SEQ ID NO: 225, la CDRH3 es el SEQ ID NO: 349, la CDRL1 es el SEQ ID NO: 473, la CDRL2 es el SEQ ID NO: 597, y la CDRL3 es el SEQ ID NO: 721.

公开(公告)号：CA2756053C

公开(公告)日：2018-10-30

申请号：CA2756053

申请日：2009-07-10

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  YU ALICE ,  CHANG YA-JEN ,  LIN KUN-HSIEN ,  HUNG JUNG-TUNG

IPC: A61K39/39 ,  A61K31/70 ,  A61P31/04 ,  A61P31/16 ,  A61P35/00

Abstract: The present disclosure relates to synthetic alpha-galactosyl ceramide (.alpha.- GalCer) analogs, and their use as immunotherapies, adju-vants, and antiviral, antibacterial, and anticancer agents. In one aspect, a method of activating a cy-tokine response in a subject includes administer-ing an effective amount of a compound to a sub-ject, wherein the subject has an adaptive immune system that includes a population of cells, the population including at least one lymphocyte and at least one antigen-presenting cell, and wherein the compound is represented by the structure of formula 1 :; or a pharmaceutically acceptable salt thereof; forming a complex between the com-pound and the antigen-presenting cell, wherein the formation of the complex results in the activa-tion of a receptor on the lymphocyte; and activat-ing the lymphocyte to produce the cytokine re-sponse.

公开(公告)号：ES2570630T3

公开(公告)日：2016-05-19

申请号：ES09789075

申请日：2009-08-06

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  YU ALICE ,  YU JOHN

IPC: A61K39/00 ,  A61K39/385

Abstract: Una composición inmunogénica que comprende: (a) un glicano que consiste esencialmente en Globo H, el antígeno-3 específico de la etapa embrionaria (SSEA-3. Gb5) y el antígeno-4 específico de la etapa embrionaria (SSEA-4, sialil-Gb5), Bb4, o un fragmento inmunogénico del mismo, en el que el glicano que se conjuga con una proteína portadora es el material 197 que presenta reacción cruzada con la toxina de la difteria (DT-CRM197) o el toxoide de la difteria, a través de un enlazante; y (b) un adyuvante de α-galactosil-ceramida (α-GalCer).

公开(公告)号：AU2014201215A1

公开(公告)日：2014-04-03

申请号：AU2014201215

申请日：2014-03-05

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  YU ALICE ,  YU JOHN

IPC: A61K39/00 ,  A61K39/385

Abstract: The present invention provides for an immunogenic composition comprising (a) a glycan, such as Globo H, stage-specific embryonic antigen-3 (SSEA-3) or SSEA-4, conjugated to a carrier protein through a linker; (b) an adjuvant comprising a glycolipid, such as a-galactosyl-ceramide adjuvant, wherein the composition induces an immune response, such as a higher relative level of IgG isotype antibodies compared to IgM isotype antibodies, or neutralising antibodies against at least one antigen selected from the group consisting of Globo H, Gb4, SSEA-3, and SSEA-4. Uses of the immunogenic composition for treating or inhibiting tumour growth are also provided.

公开(公告)号：AU2009269127B2

公开(公告)日：2013-12-05

申请号：AU2009269127

申请日：2009-08-06

Applicant: ACADEMIA SINICA

Inventor： YU ALICE ,  WONG CHI-HUEY ,  YU JOHN ,  WU CHUNG-YI

IPC: A61K39/00 ,  A61K39/385

Abstract: Immunogenic compositions, cancer vaccines and methods for treating cancer are provided. Compositions comprising: (a) a glycan such as Globo H or an immunogenic fragment thereof, wherein the glycan is conjugated with a carrier protein by a linker such as para-nitrophenyl; and (b) an adjuvant comprising glycolipid capable of binding CDId on a dendritic cell, such as an α-galactosyl-ceramide derivative, wherein the immunogenic composition induces an immune response that induces a higher relative level of IgG isotype antibodies as compared to IgM isotype antibodies, are provided. Immunogenic compositions comprising the carrier protein diphtheria toxin cross-reacting material 197 (DT-CRM 197) and the adjuvant C34 are provided. Antibodies generated by immunogenic compositions disclosed herein further neutralize at least one of the antigens Globo H, stage-specific embryonic antigen-3 (SSEA-3) and stage-specific embryonic antigen-4 (SSEA-4). Therapeutics against breast cancer stem cells comprising immunogenic compositions comprising Globo H, SSEA-3 or SSEA-4 conjugated with DT-CRM 197.

公开(公告)号：GB2461656B

公开(公告)日：2012-11-21

申请号：GB0917142

申请日：2009-07-10

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  YU ALICE ,  CHANG YA-JEN ,  LIN KUN-HSIEN ,  CHENG Y S EDMOND ,  JAN JIA-TSRONG ,  LIN YI-LING ,  HUNG JUNG-TUNG

IPC: C07H15/18 ,  A61K31/7034 ,  A61P31/04 ,  A61P31/12 ,  A61P31/14 ,  A61P31/16 ,  A61P31/18 ,  A61P31/20 ,  A61P35/00 ,  A61P43/00

公开(公告)号：AU2009269127A1

公开(公告)日：2010-01-14

申请号：AU2009269127

申请日：2009-08-06

Applicant: ACADEMIA SINICA

Inventor： YU ALICE ,  WONG CHI-HUEY ,  WU CHUNG-YI ,  YU JOHN

IPC: A61K39/00 ,  A61K39/385

Abstract: An immunogenic composition containing a glycan conjugate including a carrier protein, and a glycan including Globo H, an immunogenic fragment thereof, or stage-specific embryonic antigen-4 (SSEA-4), wherein the glycan is conjugated with the carrier protein through a linker.

公开(公告)号：WO2012061113A3

公开(公告)日：2012-06-21

申请号：PCT/US2011057637

申请日：2011-10-25

Applicant: ACADEMIA SINICA TAIWAN ,  YU JOHN ,  YU ALICE ,  WU H C ,  WANG SHENG-HUNG ,  I-JU CHEN

Inventor： YU JOHN ,  YU ALICE ,  WU H C ,  WANG SHENG-HUNG ,  I-JU CHEN

IPC: C07K5/10 ,  A61K38/07 ,  A61K38/10 ,  A61K49/14 ,  A61P35/00 ,  C07K7/08

CPC classification number: G06F19/16 ,  A61K9/127 ,  A61K9/1271 ,  A61K31/337 ,  A61K31/475 ,  A61K31/496 ,  A61K31/704 ,  A61K38/10 ,  A61K45/06 ,  A61K47/48815 ,  A61K47/6911 ,  A61K49/0043 ,  A61K49/0056 ,  A61K51/1234 ,  C07K5/1024 ,  C07K7/08 ,  G01N2333/47 ,  G01N2500/04 ,  A61K2300/00

Abstract: Cancer-targeting peptides having a PX1LX2 motif, in which X1 is His or an amino acid residue with a hydrophobic side chain and X2 is Pro, Phe, or Trp. Also disclosed herein are conjugates containing the cancer-targeting peptides and uses thereof in cancer treatment and diagnosis.

Abstract translation: 具有PX1LX2基序的癌症靶向肽，其中X1是His或具有疏水侧链的氨基酸残基，并且X2是Pro，Phe或Trp。 本文还公开了含有癌症靶向肽的缀合物及其在癌症治疗和诊断中的用途。

公开(公告)号：WO2010014218A2

公开(公告)日：2010-02-04

申请号：PCT/US2009004373

申请日：2009-07-29

Applicant: ACADEMIA SINICA ,  YU JOHN ,  YU ALICE ,  KUO MING-WEI ,  CHANG JUI-CHIN

Inventor： YU JOHN ,  YU ALICE ,  KUO MING-WEI ,  CHANG JUI-CHIN

IPC: C12N15/09

CPC classification number: C07K14/4747 ,  A61K48/005 ,  C07K16/18 ,  C12N15/113 ,  C12N2799/025 ,  C12Q1/6876 ,  G01N33/6854

Abstract: Methods and compositions for treating retinal diseases comprising therapeutic amounts of a compound selected from a normal Puf-A gene product, an active polypeptide fragment thereof, an analog thereof or a peptidomimetic thereof. Vectors, including AAV vectors comprising the therapeutic compound are provided. Puf-A compositions suitable for subretinal, intravitreal, topical, subconjunctival, retrobulbar, periocular, suprachoroidal, or intraocular administration are provided. Methods for screening siRNA, RNAi and shRNA, small molecules and monoclonal antibodies that inhibit Puf-A target activity and reduce apoptosis are provided.

Abstract translation: 用于治疗视网膜疾病的方法和组合物包括治疗量的选自正常Puf-A基因产物，其活性多肽片段，其类似物或肽模拟物的化合物。 提供载体，包括包含治疗化合物的AAV载体。 提供适用于视网膜下，玻璃体内，局部，结膜下结膜，球后，眼周，脉络膜或眼内给药的Puf-A组合物。 提供了筛选siRNA，RNAi和shRNA，抑制Puf-A靶活性和减少细胞凋亡的小分子和单克隆抗体的方法。

公开(公告)号：AU2009268381B2

公开(公告)日：2016-04-21

申请号：AU2009268381

申请日：2009-07-10

Applicant: ACADEMIA SINICA

Inventor： HUNG JUNG-TUNG ,  LIN KUN-HSIEN ,  YU ALICE ,  JAN JIA-TSRONG ,  CHANG YA-JEN ,  LIN YI-LING ,  WONG CHI-HUEY ,  CHENG Y S EDMOND

IPC: A61K31/70 ,  A61K39/39 ,  A61P31/04 ,  A61P31/16 ,  A61P35/00

Abstract: The present disclosure relates to synthetic alpha-galactosyl ceramide (α- GalCer) analogs, and their use as immunotherapies, adjuvants, and antiviral, antibacterial, and anticancer agents. In one aspect, a method of activating a cytokine response in a subject includes administering an effective amount of a compound to a subject, wherein the subject has an adaptive immune system that includes a population of cells, the population including at least one lymphocyte and at least one antigen-presenting cell, and wherein the compound is represented by the structure of formula 1 :; or a pharmaceutically acceptable salt thereof; forming a complex between the compound and the antigen-presenting cell, wherein the formation of the complex results in the activation of a receptor on the lymphocyte; and activating the lymphocyte to produce the cytokine response.